BCYC News and Press, Bicycle Therapeutics plc From 09/24/19

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycles ® ) product platform, today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evalua...

Shares of little known UK-based biotech firm Bicycle Therapeutics ( BCYC ) have fallen by roughly 30% since IPO was priced at $14 in late May. On the other hand, the stock has recently experienced multiple days of relatively higher accumulation (rising by 43% over the past week). I had bee...

Bicycle Therapeutics (BCYC) (“the company”) was founded in 2009 and is based in Cambridge, the UK, and Cambridge, Massachusetts. What are Bicycle peptides: Bicycle peptides are fully synthetic short peptides constrained to form two loops using a chemical connector compound ...

Gainers : Fibrocell Science (NASDAQ: FCSC ) +60% . Mer Telemanagement Solutions (NASDAQ: MTSL ) +40% . Francesca's Holdings Corporation (NASDAQ: FRAN ) +30% . OpGen (NASDAQ: OPGN ) +26% . Vince Holding (NYSE: VNCE ) +24% . ASLAN Pharmaceuticals Limited (NASDAQ: ASLN ) +22% . Medallia...

Gainers:  Yuma Energy (NYSEMKT: YUMA ) +145% . T2 Biosystems (NASDAQ: TTOO ) +57% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +29% . Bicycle Therapeutics (NASDAQ: BCYC ) +25% . CARBO Ceramics (NYSE: CRR ) +23% . Luby's (NYSE: LUB ) +23% . CBL & Associates Properties (NYSE: CBL...

Oramed Pharmaceuticals (NASDAQ: ORMP ) initiated with Buy rating and $7 (136% upside) at Ladenburg Thalmann. Shares up  3%  premarket. More news on: Oramed Pharmaceuticals Inc., PhaseBio Pharmaceuticals, Inc., Bicycle Therapeutics plc, Healthcare stocks news, Stocks on the move, ...

- Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors - Successfully completed initial public offering (IPO) raising gross proceeds of $64.9 million - Strengthened Board of Directors and clinical leadership team Bic...

Bicycle Therapeutics plc , a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will present at the Canaccord Genuity 39 th Annual Growth Conference on Wednesday, August 7, 20...

Appoints pharmaceutical industry veteran Richard N. Kender, MBA, and life sciences financing professional Janice Bourque, MBA Orderly transition planned for four board members to depart over the next 12 months Bicycle Therapeutics plc , a biotechnology company pioneering a new c...

Thinly traded micro cap Bicycle Therapeutics (NASDAQ: BCYC ) is up  10%  premarket on light volume on the heels of encouraging data from an open-label Phase 1 clinical trial evaluating a single intravitreal injection of THR-149, a Bicycle-based plasma kallikrein inhibitor, in pat...